Abstract：
:Earlier, we reported an association of A-kinase anchor protein 4 (AKAP4) expression in cervical cancer patient specimens, indicating its implications as an immunotherapeutic target. In this study, we investigated the possible role of AKAP4 in cervical carcinogenesis. AKAP4 messenger RNA and protein expression was assessed in four cervical cancer cell line models, C-33A, CaSki, HeLa and SiHa. Gene silencing approach was employed to investigate the potential role of AKAP4 in cellular growth, proliferation, colony-forming ability, migration and invasion in aggressive squamous cell carcinoma cells (SiHa). Further, the effect of downregulation of AKAP4 on tumor growth was examined in the cervical cancer xenograft model in nude mice. Our data clearly indicated that AKAP4 was expressed in all cervical cancer cells at the gene and protein level. We also observed distinct cytoplasmic and surface localization by indirect immunofluorescence and flow cytometry, respectively. Ablation of AKAP4 protein caused significant inhibition in cellular proliferation, colony-forming ability, migration and invasion ability of SiHa cells. Further, gene silencing of AKAP4 also resulted in reduced tumor growth in nude mice in vivo. Collectively, AKAP4 surface localization and its significant association with malignant properties of cervical cancer cells imply its clinical utility as an immunotherapeutic target.
journal_name
Cancer Gene Therjournal_title
Cancer gene therapyauthors
Saini S,Agarwal S,Sinha A,Verma A,Parashar D,Gupta N,Ansari AS,Lohiya NK,Jagadish N,Suri Adoi
10.1038/cgt.2013.32subject
Has Abstractpub_date
2013-07-01 00:00:00pages
413-20issue
7eissn
0929-1903issn
1476-5500pii
cgt201332journal_volume
20pub_type
杂志文章abstract：:We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3-interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of E1A proteins to p300/CBP and pRB. The antitumor activity of the vectors was enhanced by overexpression of the Adenoviru...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7701107
更新日期：2008-02-01 00:00:00
abstract：:Cis-diamminedichloroplatinum(II) increased in vivo lipofection efficiency of tumor cells with a target gene, interferon gamma (IFN gamma), in a murine metastatic ovarian carcinoma model. The expression of IFN gamma gene in ascitic tumors reached a peak at day 11 after cisplatin treatment and lasted over 1 week. A loca...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：
更新日期：1997-11-01 00:00:00
abstract：:The success of cancer gene therapies requiring in vivo gene transfer is severely hampered by the low efficacy of gene transfer, which has been difficult to improve. We therefore established a novel strategy to increase the share of transduced cells post gene transfer. We hypothesized that in vivo selection of tumor ce...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700995
更新日期：2007-01-01 00:00:00
abstract：:Use of a recombinant vaccinia virus expressing human interleukin-2 (IL-2) was evaluated for preparation of tumor vaccines. A/J mice were immunized against neuroblastoma (C1300) cells using a preparation of C1300 cells infected/transfected with the recombinant virus, vCF13, expressing IL-2. A second recombinant vaccini...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：
更新日期：1996-05-01 00:00:00
abstract：:Cationic liposomes are considered to be safe vectors for gene transfer, but they are less efficient at delivering DNA to cells when compared with retroviral vectors. Cationic liposomes complexed with DNA were targeted to specific cells in vitro by means of monoclonal antibodies (mAbs) or ligands associated with the li...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：
更新日期：1996-07-01 00:00:00
abstract：:Chemotherapy remains the main tool for the treatment of cancers, but is often hampered by tumor cell resistance. In this context, the transfer of genes able to accentuate the effect of anticancer drugs may constitute a useful approach, as exemplified by inactivation of nuclear factor (NF)-kappa B via direct transfer o...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700467
更新日期：2002-06-01 00:00:00
abstract：:Angiogenesis is among the most important mechanisms that helps cancer cells to survive, grow and undergo metastasis. Therefore, inhibiting angiogenesis will suppress tumor growth. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are believed to be important players of angiogenesis. The goal of this s...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2016.76
更新日期：2017-01-01 00:00:00
abstract：:Gene therapy designed to initiate apoptotic cell death provides a potentially effective method to treat cancer. A prerequisite for this approach is the identification of genes that function in distinct apoptotic pathways. Although apoptotic pathways initiated by receptors such as tumor necrosis factor receptor-1 are w...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700194
更新日期：2000-07-01 00:00:00
abstract：:Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers. Although the cure rate for sarcomas in general has significantly improved in the last 10 years, there continue to be subgroups that are difficult to treat. High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of ...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700798
更新日期：2005-04-01 00:00:00
abstract：:Doublecortin-like kinase 1 (DCLK1) is a cancer stem cell marker for the colorectal cancer (CRC). It plays critical roles in the oncogenesis, progression, and metastasis of CRC. DCLK1 can be an intriguing therapeutic target for CRC treatment. However, the molecular mechanism of how DCLK1 functions is unclear currently....
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/s41417-019-0144-4
更新日期：2020-09-01 00:00:00
abstract：:We have constructed and tested five recombinant adenoviruses (Ads) that express a variety of immunomodulators, including CD40 ligand (CD40L), a potent costimulator of several components of the immune system. We demonstrate that CD40L expressed from Ad in K1735 mouse melanoma cells leads to a strong reduction in tumori...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700475
更新日期：2002-07-01 00:00:00
abstract：:Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such ...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700967
更新日期：2006-10-01 00:00:00
abstract：:The ability of viruses to readily infect tumor cells both in vitro and in vivo has resulted in their study as antitumor agents through a variety of strategies. Replicating and conditionally replicating viruses and recombinant viruses encoding genes for toxins and/or prodrugs have been studied for their direct antitumo...
journal_title：Cancer gene therapy
pub_type： 杂志文章,评审
doi：10.1038/sj.cgt.7700538
更新日期：2002-12-01 00:00:00
abstract：:In this study, we have applied high-density oligonucleotide microarray technology to characterize biologic changes associated with adenoviral vector-mediated target cell infection. We infected a human melanoma cell line, M21, with the tropism-modified vectors, Ad5lucRGD and Ad5/3luc1. In addition, we infected the M21 ...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700776
更新日期：2005-02-01 00:00:00
abstract：:Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is needed to resolve this discrepancy. In the clinic, OV therapy will likely be combined with traditional chemotherapy, und...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2012.33
更新日期：2012-08-01 00:00:00
abstract：:Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2010.4
更新日期：2010-07-01 00:00:00
abstract：:Lung cancer is one of the leading causes of death in the world. The underlying cause for lung cancer has been attributed to various factors that include alteration and mutation in the tumor suppressor genes. Restoration of normal function of the tumor suppressor gene is a potential therapeutic strategy. Recent studies...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700756
更新日期：2004-11-01 00:00:00
abstract：:Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-relate...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/s41417-018-0070-x
更新日期：2019-11-01 00:00:00
abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2010.22
更新日期：2010-09-01 00:00:00
abstract：:A novel gene, HA117, was discovered in our previous work. Using the pSOS-HUS vector method which we designed at previous study, we screened for small interfering RNAs (siRNAs) that targeted HA117. The pSOS-HUS siRNA screening results were verified and a delivery system was developed that contained a recombinant adenov...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2011.32
更新日期：2011-09-01 00:00:00
abstract：:Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer deaths in Americans. The high mortality rate is mainly attributed to the invasiveness and metastasis of advanced prostate cancer. Targeting the molecules involved in metastasis could be an effective mode of treatment f...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2010.16
更新日期：2010-09-01 00:00:00
abstract：:Intratumoral (i.t.) administration of cytokine genes expressed by viral vectors represents a rational approach that induces cytokine secretion at the site they are needed, and i.t. vaccinia virus (VV) has shown promise in mesothelioma patients. However, we and others have shown that the mesothelioma tumor microenviron...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2009.85
更新日期：2010-06-01 00:00:00
abstract：:Bcl-2 is associated with resistance to radiotherapy in prostate cancer. It was recently demonstrated that transduction of LNCaP prostate cells with the PTEN gene resulted in Bcl-2 downregulation. We hypothesized that forced expression of PTEN in prostate cancer cells would sensitize cells to radiation, downregulate Bc...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700673
更新日期：2004-04-01 00:00:00
abstract：:In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid-based "splice-activated gene expression" (pSAGE) vectors was generated, which contain minigene cassettes composed of various combinations of the t...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700427
更新日期：2002-02-01 00:00:00
abstract：:One of the challenges of oncolytic virotherapy is the inability to easily track or monitor virus activity during treatment. Here we describe the construction and functional characterization of Ad/hTC-GFP-E1, an oncolytic virus whose transgenes GFP and E1A are both under the control of a synthetic promoter (hTC). This ...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700944
更新日期：2006-07-01 00:00:00
abstract：:Melanoma incidence is growing at a faster rate than any other human malignancy. Wild-type (wt) p53 is important in both G(1) and G(2) cell cycle arrest, and cyclin D1 (CD1) is necessary for G(1)-->S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [(3)H]thymi...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700492
更新日期：2002-10-01 00:00:00
abstract：:MicroRNAs (miRNAs) are important regulators that play key roles in tumorigenesis and tumor progression. In this study, we investigate whether let-7b acts as a tumor suppressor to inhibit invasion and metastasis in gastric cancers. We analyzed the expression of let-7b in 60 pair-matched gastric neoplastic and adjacent ...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2014.75
更新日期：2015-04-01 00:00:00
abstract：:Clear cell renal cell carcinoma (ccRCC) is the highest mortality, invasion, and metastasis subtype of renal cell carcinoma. Bone morphogenetic protein (BMP) family has recently emerged as a group of cancer-related proteins in multiple pathogenesis of cancers. Currently, little is known about the prediction role of BMP...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/s41417-019-0107-9
更新日期：2020-05-01 00:00:00
abstract：:Gene-directed enzyme prodrug therapy (GDEPT) is a promising approach to local management of cancer through targeted chemotherapy. Killing localized tumors by GDEPT in a manner that induces strong antitumor cellular immune responses might improve local management and allow benefit in disseminated cancer. Here we evalua...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/sj.cgt.7700807
更新日期：2005-06-01 00:00:00
abstract：:A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies ha...
journal_title：Cancer gene therapy
pub_type： 杂志文章
doi：10.1038/cgt.2009.39
更新日期：2009-12-01 00:00:00
